The smooth transition of the EU drug agency from London to Amsterdam is threatened by delays in the Netherlands, whose bid to win the agency may have been misleading, a top representative of Italian pharmaceuticals told EURACTIV.com.
Dutch officials and the head of the European Medicines Agency (EMA) sought yesterday (29 January) to allay any jitters among the agency's 900 London-based staff who are being asked to move to Amsterdam because of Britain's departure from the EU.
Public health organisations and EU lawmakers say the closed-door meetings before the submission of a new drug between the pharma industry and the European Medicines Agency (EMA), a key player in the continent’s healthcare industry, should be more transparent.
At the end of a suspenseful day, delegates from 27 EU governments meeting in the General Affairs Council chose to relocate the European Medicines Agency to Amsterdam and the European Banking Authority to Paris. EURACTIV France reports.
Amsterdam and Paris won the right to host the two EU agencies that must leave London on Brexit after a dramatic ministerial meeting in Brussels on Monday (20 November) that left both result decided by drawing lots after votes were tied.
EU ministers will vote by secret ballot on the relocation of two EU agencies currently based in London at the General Affairs Council on 20 November. The ballot papers will then be destroyed and no record kept.
The competition for the European Medicines Agency is not a horse race but the first concrete, effective decision the EU has to make in the wake of Brexit - and one with long-lasting consequences. A responsible yet ambitious mindset is therefore in order, writes Sandro Gozi.
In assessing the relocation of the EU drugs agency EMA, old member states have a "moral and political obligation" to give an advantage to those candidate countries that do not currently host another EU agency, Croatia’s health minister told EURACTIV.com.
Athens’ decision to claim the European Medicine Agency's relocation from London sends a message that medicine is “not just a commodity but a social good”, Greece’s Alternate Minister of Foreign Affairs, Georgios Katrougalos, told EURACTIV.com.
The European Medicines Agency (EMA) presented on Tuesday (1 August) a business continuity plan aimed at tackling the potential challenges poised by its relocation from London to another member state after the Brexit decision.
Hosting the European Medicines Agency brings considerable economic benefits to the host city as the service employs more than 1,000 people, paid by the EU. Athens and Milan are keen to secure a slice of this lucrative pie.
Spanish Minister for Health Dolors Montserrat said today (24 May) that Barcelona is “first in the class” in meeting all the criteria to host the European Medicines Agency (EMA). She also insisted that the central government supports Catalonia's bid to host it after Brexit.
Portugal is the latest member state to try and poach the UK-based European Medicines Agency after Brexit. In an interview with EURACTIV.com, Portugal’s junior minister for European affairs insisted having two EU agencies based in Lisbon already would not hurt its chances.
EU officials claim there is growing support for a proposal to close the European Parliament’s expensive second seat in Strasbourg and to sweeten the deal by giving the French city the European Medicine Agency in return.
Public sector jobs in the United Kingdom and in the EU itself are far from safe from the uncertainty generated by Brexit. UK public services are already suffering and British civil servants could be put out to pasture by Brussels.
Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU.